Vanda Pharmaceuticals
Nasdaq VNDA · Washington, DC
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Ophthalmology · Psychiatry · Respiratory
Vanda Pharmaceuticals is a clinical trial sponsor based in Washington, DC, listed as Nasdaq VNDA. It has 17 active clinical trials with 5,008 planned participants, across 12 therapeutic areas. Since 2021 it has completed 32 trials and stopped 5 early.
Trial track record · since 2021
Financials · Nasdaq VNDA
Fundraising
No SEC Form D filings under this name. A private round is only public when the company files one.
Pipeline · 17 active trials
| Stage | Trial | Status |
|---|---|---|
On the market · 6 products
- HETLIOZ LQ tasimelteon · NDA 214517 · prescription
- NEREUS tradipitant · NDA 220152 · prescription
- PONVORY ponesimod · NDA 213498 · prescription
- BYSANTI milsaperidone · NDA 220358 · prescription
- FANAPT iloperidone · NDA 022192 · prescription
- HETLIOZ tasimelteon · NDA 205677 · prescription
Questions about Vanda Pharmaceuticals
Vanda Pharmaceuticals is lead sponsor of 17 active clinical trials on ClinicalTrials.gov, with 5,008 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 32 trials and stopped 5 early.
Vanda Pharmaceuticals is based in Washington, DC and is listed as Nasdaq VNDA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Vanda Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-23.
Approve Suite is not affiliated with Vanda Pharmaceuticals.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.